









Markets
/
Stocks
/
nasdaq-cgon
/

CG Oncology Inc

CGON

39.980USD

-0.240-0.60%

Market hours （ET）Quotes delayed by 15 min

3.05BMarket Cap

LossP/E TTM



CG Oncology Inc

39.980

-0.240-0.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CG Oncology Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CG Oncology Inc's Score

Industry at a Glance

Industry Ranking

57 / 407

Overall Ranking

165 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

70.200

Target Price

+76.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CG Oncology Inc Highlights

StrengthsRisks

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 496.34% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.14M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.14M.

Fairly Valued

The company’s latest PE is -22.67, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.62M shares, decreasing 0.91% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 1.48M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 6.31, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 119.16%.

Score

Industry at a Glance

Previous score

6.31

Change



Financials

6.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.61

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.46

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

CG Oncology Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 7.06, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -22.67, which is -57.20% below the recent high of -9.70 and -97.96% above the recent low of -44.88.

Score

Industry at a Glance

Previous score

7.06

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 57/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.31, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for CG Oncology Inc is 75.00, with a high of 90.00 and a low of 53.00.

Score

Industry at a Glance

Previous score

8.31

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

70.200

Target Price

+76.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

CG Oncology Inc

CGON

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 6.67, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 44.45 and the support level at 36.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-1.385

Neutral

RSI(14)

48.727

Neutral

STOCH(KDJ)(9,3,3)

37.148

Buy

ATR(14)

2.016

Low Volatility

CCI(14)

-48.266

Neutral

Williams %R

61.985

Sell

TRIX(12,20)

0.097

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

39.324

Buy

MA10

41.095

Sell

MA20

41.933

Sell

MA50

38.807

Buy

MA100

32.470

Buy

MA200

29.004

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 114.91%, representing a quarter-over-quarter increase of 7.25%. The largest institutional shareholder is The Vanguard, holding a total of 6.57M shares, representing 8.61% of shares outstanding, with 12.10% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.90M

+1.20%

Decheng Capital LLC

6.37M

Longitude Capital Management Co., LLC

4.66M

BlackRock Institutional Trust Company, N.A.

3.82M

-1.09%

Fidelity Management & Research Company LLC

3.72M

+53.90%

TCG Crossover Management, LLC

3.67M

ORI Capital Limited

3.58M

-0.29%

Braidwell LP

3.28M

Foresite Capital Management, LLC

3.23M

+4.71%

Kynam Capital Management LP

2.46M

-5.90%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 5.58, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.